

PAPER

## The role of aquaporins in the anti-glioblastoma capacity of the cold plasma-stimulated medium

To cite this article: Dayun Yan *et al* 2017 *J. Phys. D: Appl. Phys.* **50** 055401

### Manuscript version: Accepted Manuscript

Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”

This Accepted Manuscript is© .

During the embargo period (the 12 month period from the publication of the Version of Record of this article), the Accepted Manuscript is fully protected by copyright and cannot be reused or reposted elsewhere.

As the Version of Record of this article is going to be / has been published on a subscription basis, this Accepted Manuscript will be available for reuse under a CC BY-NC-ND 3.0 licence after the 12 month embargo period.

After the embargo period, everyone is permitted to use copy and redistribute this article for non-commercial purposes only, provided that they adhere to all the terms of the licence <https://creativecommons.org/licenses/by-nc-nd/3.0>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions may be required. All third party content is fully copyright protected, unless specifically stated otherwise in the figure caption in the Version of Record.

View the [article online](#) for updates and enhancements.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## The role of aquaporins in the anti-glioblastoma capacity of the cold plasma-stimulated medium

Dayun Yan<sup>1†</sup>, Haijie Xiao<sup>2†</sup>, Wei Zhu<sup>1</sup>, Niki Nourmohammadi<sup>3</sup>, Lijie Grace Zhang<sup>1</sup>, Ka Bian<sup>2\*</sup>,  
and Michael Keidar<sup>1\*</sup>

<sup>1</sup>Department of Mechanical and Aerospace Engineering, The George Washington University, Science & Engineering Hall, 800 22<sup>nd</sup> Street, NW, Room 3550, Washington, DC 20052, USA

<sup>2</sup>Department of Biochemistry and Molecular Medicine, The George Washington University, Ross Hall, 2300 Eye Street, NW, Washington, DC 20037, USA

<sup>3</sup>Department of Biological Sciences, The George Washington University, Lisner Hall, 2023 G Street, NW, Suite 340, Washington, DC 20052, USA

<sup>†</sup>These two authors contribute equally to this research.

\*Corresponding authors: Ka Bian [bcmkxb@gwu.edu](mailto:bcmkxb@gwu.edu), Michael Keidar [keidar@gwu.edu](mailto:keidar@gwu.edu)

**Abstract.** The cold atmospheric plasma (CAP) is a promising novel anti-cancer method. Our previous study showed that the cold plasma-stimulated medium (PSM) exerts remarkable anti-cancer effect as effectively as the direct CAP treatment does. H<sub>2</sub>O<sub>2</sub> has been identified as a key anti-cancer substance in PSM. However, the mechanisms underlying intracellular H<sub>2</sub>O<sub>2</sub> regulation by cancer cells is largely unknown. Aquaporins (AQPs) are the confirmed membrane channels of H<sub>2</sub>O<sub>2</sub>. In this study, we first demonstrated that the anti-glioblastoma capacity of PSM could be inhibited by silencing the expression of AQP8 in glioblastoma cells (U87MG) or using the

1  
2  
3 aquaporins-blocker silver atoms. This discovery illustrates the key intermediate role of AQPs in  
4 the toxicity of PSM on cancer cells. Because expression of AQPs varies significantly among  
5 different cancer cell lines, this study may facilitate the understanding on the diverse responses of  
6 cancer cells to PSM or the direct CAP treatment.  
7  
8  
9  
10  
11  
12  
13  
14

## 15 **Introduction.**

16  
17 Cancer is one of the largest threats to human health. Developing a novel anti-cancer method with  
18 minimal damage to normal cells and tissues is always the goal of scientists. Cold atmospheric  
19 plasma (CAP), a near-room temperature ionized gas composed of reactive electrons, ionic, atomic,  
20 molecular, and radical species [1], showed a remarkable selective anti-cancer capacity over dozens  
21 of cancer cell lines *in vitro* [2-12] and in several animal studies *in vivo* [5, 13-15]. Recently, the  
22 direct plasma treatment by the CAP jet or the dielectric barrier discharge (DBD) and the cold  
23 plasma-stimulated medium (PSM) has been proved to be a selective anti-cancer method [16-25].  
24 PSM can be stably stored over a wide temperature range, by regulating the component of medium  
25 [26] or controlling the storage temperature [27, 28]. PSM can be used as a succedaneum for CAP  
26 particularly in the circumstances when some inside tumorous tissues cannot be easily reached by  
27 CAP jet.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Understanding the anti-cancer mechanism of CAP is a challenge in plasma medicine. PSM is also  
47 named as the indirect CAP treatment. In contrast, the direct CAP treatment denotes the CAP  
48 treatment on cells cultured in petri dishes [7, 29, 30] or in multi-wells plates [31-33]. So far, in  
49 many cases, the cells were immersed in a layer of cell culture medium during the direct CAP  
50 treatment [34-36]. Such layer of medium plays the intermediate role of delivering the plasma-  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 originated reactive species from gas phase into the aqueous solution and further affecting cells  
4  
5 [37]. Thus, understanding anti-cancer mechanism of PSM will also facilitate the understanding on  
6  
7 the direct CAP treatment on cancer cells *in vitro*.  
8  
9

10  
11  
12 So far, among diverse CAP-originated species, H<sub>2</sub>O<sub>2</sub>, has been proved to be one of main anti-  
13  
14 cancer reactive species of PSM [19, 20, 23, 26-28, 38]. Very recently, synergistically using  
15  
16 H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>-</sup> [22] or H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>-</sup>/NO<sub>3</sub><sup>-</sup> [25] in medium [22] or phosphate buffered saline (PBS) [25]  
17  
18 generated a similar anti-cancer effect as PSM did. Thus, ROS mainly H<sub>2</sub>O<sub>2</sub> and RNS mainly NO<sub>2</sub><sup>-</sup>  
19  
20 /NO<sub>3</sub><sup>-</sup> in PSM contribute to the death of cancer cells. RNS in PSM was showed to play a minor  
21  
22 anti-cancer role [22, 25]. According to the current conclusions, the anti-cancer mechanism of PSM  
23  
24 is largely based on the interaction between ROS mainly H<sub>2</sub>O<sub>2</sub> and cancer cells.  
25  
26  
27  
28  
29  
30

31  
32 Since most of plasma-originated reactive species are either charged or polar molecules, specific  
33  
34 channels and transporters on the cytoplasmic membrane are necessary for the transmembrane  
35  
36 diffusion of these reactive species. The membrane proteins may be a key to understand the cellular  
37  
38 response to the CAP treatment. However, the role of membrane channels of cancer cells in the  
39  
40 anti-cancer mechanism of PSM or direct CAP treatment has never been investigated yet.  
41  
42 Aquaporins (AQPs) were first discovered as the specific water channel decades ago [39]. Recently,  
43  
44 the key role of AQPs in the transmembrane diffusion of several small molecules including H<sub>2</sub>O<sub>2</sub>,  
45  
46 CO<sub>2</sub>, NO, NH<sub>3</sub>, urea, and glycerol has been unveiled [40]. Among AQPs family, only AQP 1, 3,  
47  
48 8, and 9 have been confirmed as the membrane channels facilitating the H<sub>2</sub>O<sub>2</sub> transmembrane  
49  
50 diffusion [41-45]. In contrast with AQP1, AQP8 is able to better facilitate the diffusion of H<sub>2</sub>O<sub>2</sub>  
51  
52 across the cellular membrane of yeast cells [43], which may be partially due to the large average  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 diameter of the ar/R constriction regions of AQP8 [2, 43]. The yeast cells without AQPs show a  
4 strong resistance to high concentration extracellular H<sub>2</sub>O<sub>2</sub> [43]. On the contrary, the expression of  
5 AQP8 causes a significant yeast cell death upon the treatment of low concentration extracellular  
6 H<sub>2</sub>O<sub>2</sub> [43]. Thus, AQPs may play a key role in the anti-cancer capacity of PSM particularly in the  
7 transmembrane diffusion of plasma-originated H<sub>2</sub>O<sub>2</sub>.  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 In this study, we first investigated the expression of AQPs in glioblastoma cells (U87MG). AQP9  
18 show the highest expression among all AQPs. We then inhibited the expression of AQP8 and  
19 AQP9 in U87MG cells by siRNA technology and found that the anti-glioblastoma effect of PSM  
20 were significantly inhibited by silencing AQP8 but not by silencing AQP9. Corresponding rise of  
21 intracellular ROS in U87MG cells were also inhibited by silencing AQP8. We also demonstrated  
22 that the anti-glioblastoma capacity of PSM can be significantly inhibited by adding AgNO<sub>3</sub> which  
23 can block the water channels of AQPs [46, 47]. This study demonstrates that AQPs play a key  
24 intermediate role in the anti-cancer capacity of PSM.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Methods.**

40 **CAP device.** The CAP device was a CAP jet generator using helium as the carrying gas. This CAP  
41 jet has been used to study the anti-cancer effect of the direct CAP treatment [30, 48] and PSM [18,  
42 19, 24, 26]. The violet plasma was generated between a ring grounded cathode and a central anode  
43 and was ejected out from a quartz tube with a diameter of 4.5 mm. The helium gas flowed at a rate  
44 of 4.7 L/min. The input voltage of DC power was 11.5 V. The output voltage was 3.16 kV. The  
45 plasma discharge was driven by an alternating current (AC) high voltage with a frequency of 30  
46 kHz. The emission spectrum of CAP has been measured in previous study, demonstrating that  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 CAP in the gas phase was mainly composed of ROS (OH<sup>•</sup>, O), RNS (NO, N<sub>2</sub><sup>+</sup>), and helium (He)  
4  
5 [49].  
6  
7  
8  
9

10 **Cell cultures.** Standard DMEM was purchased from Life Technologies (11965-118, with L-  
11 glutamine). DMEM was mixed with 1% (v/v) antibiotic (penicillin and streptomycin) solution  
12 (Life Technologies). Human glioblastoma (U87MG) cells were provided by Dr. Murad's lab at the  
13 George Washington University. The media used in the cell seeding process and initial cell culture  
14 were composed of DMEM supplemented with 10% (v/v) fetal bovine serum (ThermoFisher  
15 Scientific) and 1% (v/v) antibiotic (penicillin and streptomycin) solution (Life Technologies). In  
16 each experiment, 6 wells in a single column on 96-well plate were seeded with cancer cells at a  
17 concentration of  $3 \times 10^4$  cells/ml in 100  $\mu$ L and were grown for 8 hours under the standard cell  
18 culture conditions (a humidified, 37°C, 5% CO<sub>2</sub> environment). All wells on the margins of 96-  
19 well plate have not been used in experiments. When PSM was used to treat glioblastoma cells, the  
20 medium which have been used to grow cells for 8 hours were removed first.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 **cDNA synthesis and quantitative PCR.** RNA purification was performed by using TRIzol  
40 (ThermoFisher) according to the manufactures' instruction. Briefly, 1 mL of TRIzol was added  
41 into U87MG cells of  $10^6$  grown in culture dish after medium was removed and cells were then  
42 scraped from the dish and transferred to eppendorf tube. After 5 min of incubation at room  
43 temperature, 200  $\mu$ L of chloroform was then added into the cell lysate and tube was shook  
44 vigorously for about 15 s. After incubation at room temperature for 3 min, the mixture was  
45 centrifuged at 12,000 g for 15 min at 40°C. Then 500  $\mu$ L of isopropanol was added into the  
46 aqueous phase and the mixture was incubated at room temperature for 10 min. RNA was  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

precipitated at 14,000 g for 10 min and then washed with 1 mL 75% ethanol. The precipitated RNA was air dry for 5-10 min and then re-suspended in 50  $\mu$ L of H<sub>2</sub>O.

cDNA was made by using iScript cDNA synthesis kit from Bio-Rad company with 1 $\mu$ g of RNA in 20  $\mu$ L of reaction under the following condition: incubation at 25°C for 5 min followed by 42°C for 30 min and 85°C for 5 min. Quantitative real time PCR was performed by using SYBR green reagent (Bio-Rad 170-880) with a CFX96 system at the following condition: 95 °C initial denaturation 3 min followed by 40 cycles of denaturation at 95 °C for 15 s, annealing and elongation at 60 °C for 30 s, Primers used in this study are shown in [Table 1](#).

**Table 1. Primers of AQPs used in this study.** F: forward; R: Reverse.

Genes	Sequence (5'-3')	Expected PCR product size (bp)
AQP1	<b>F:</b> CCTGGCTATTGACTACAC; <b>R:</b> GAAGTCGTAGATGAGTACA.	147
AQP2	<b>F:</b> CCACCTCCTTGGGATCCATTA; <b>R:</b> AGGGGTCCGATCCAGAAGAC.	114
AQP3	<b>F:</b> ACCAGCTTTTTGTTTCGGGC; <b>R:</b> GGCTGTGCCTATGAACTGGT.	110
AQP4	<b>F:</b> ACTGGTGCCAGCATGAATCC; <b>R:</b> GGGCCCAACCCAATATATCCAA.	90
AQP5	<b>F:</b> GCTCACTGGGTTTTCTGGGTA; <b>R:</b> CCTCGTCAGGCTCATACGTG.	139
AQP6	<b>F:</b> TCGTAGGCTCCACATCTCT; <b>R:</b> CTGTTCCGGACCACGTTGAT.	145
AQP7	<b>F:</b> GGACAGTCACGGAGGAACAA; <b>R:</b> TCAGATTTGTAGATGTCTGCTGAA.	102
AQP8	<b>F:</b> GTGCCTGTCCGGTCATTGAGA; <b>R:</b> CAGGGTTGAAGTGCCACCA.	125
AQP9	<b>F:</b> TCCTCAGAGAAGCCCAAGA; <b>R:</b> AGCCACATCCAAGGACAATCA.	146
AQP10	<b>F:</b> TGTTTGTACTCATGCAGCTCCT; <b>R:</b> GGCTATCGTAACGGCCAGAG.	119
AQP11	<b>F:</b> CCAGGAAGTCCGAACCAAGC; <b>R:</b> CCTGTTAGACTTCCTCCTGCATA.	84
AQP12	<b>F:</b> TGGCAGGTCTTAACGTGTCC; <b>R:</b> CAGCGTCCTCATCGCCTC.	13

**AQP8 and AQP9 knockdown.** The on-target plus smartpool siAQP8 and siAQP9 were purchased from Dharmacon and siRNA transfection was performed by using Lipofectamine RNAiMAX

1  
2  
3 (Invitrogen 13778) according to the manufactures' instruction. Basically, U87MG cells grown to  
4  
5 50% confluence in 6-well culture dish were washed with OPTI low serum medium (Invitrogen,  
6  
7 31985) and then transfected with 4  $\mu\text{L}$  of siAQP8 or siAQP9 (10  $\mu\text{M}$ ) together with 4  $\mu\text{L}$  of  
8  
9 Lipofectamine RNAiMAX in OPTI medium for each well. Universal negative control siRNA  
10  
11 (Sigma, sic001) was used as a negative control. After 6 hr of transfection, cells were changed back  
12  
13 to DMEM medium which was supplemented with 10% FBS. Quantitative real time PCR was then  
14  
15 performed to confirm the AQP8 and AQP9 genes expression.  
16  
17  
18  
19  
20  
21

22 **Making PSM and affecting the growth of glioblastoma cells.** The DMEM used in this study  
23  
24 was made by mixing 1% (v/v) penicillin-streptomycin (Life Technologies) with standard DMEM  
25  
26 (11965-118, Life Technologies). During the CAP treatment, 1 mL of DMEM in a well of 12-well  
27  
28 plate was treated by CAP for a specific time length. The gap between the bottom of 12-well plate  
29  
30 and the source of CAP was 3 cm. After that, 100  $\mu\text{L}$  of plasma-stimulated DMEM was used to  
31  
32 affect the growth of U87MG cells in each well immediately. The control group was the case that  
33  
34 U87MG cells cultured in DMEM without the CAP treatment. The sample number in each case  
35  
36 was 6. Thus, only 600  $\mu\text{L}$  in each 1 mL of plasma-stimulated DMEM were transferred to affect  
37  
38 U87MG cells. Glioblastoma cells were cultured for 2 days before the cell viability was measured  
39  
40 by MTT assay. The sextuplicate experiments were independently repeated for twice.  
41  
42  
43  
44  
45  
46  
47

48 **Measuring  $\text{H}_2\text{O}_2$  concentration in DMEM.** The  $\text{H}_2\text{O}_2$  concentration in PSM was measured by  
49  
50 using Fluorimetric Hydrogen Peroxide Assay Kit (Sigma-Aldrich) according to the protocols  
51  
52 provided by manufacturer. A H1 microplate reader (Hybrid Technology) was used to measure the  
53  
54 fluorescence with an excitation wavelength at 540 nm and an emission wavelength at 590 nm. The  
55  
56  
57  
58  
59  
60

1  
2  
3 final fluorescent strength of the experimental group was obtained by deducting the measured  
4  
5 fluorescent strength of the control group from the measured fluorescent strength of the  
6  
7 experimental group. The standard H<sub>2</sub>O<sub>2</sub> solution (Sigma-Aldrich) was used to prepare the standard  
8  
9 H<sub>2</sub>O<sub>2</sub> concentration-fluorescence curve. Based on this standard concentration-fluorescence curve,  
10  
11 the H<sub>2</sub>O<sub>2</sub> concentration in the plasma-treated DMEM was obtained.  
12  
13  
14  
15  
16

17 **Making the H<sub>2</sub>O<sub>2</sub>-rich DMEM and affecting the growth of glioblastoma cells.** The H<sub>2</sub>O<sub>2</sub>-  
18  
19 rich DMEM was prepared by mixing 30 wt % (9.8 M) H<sub>2</sub>O<sub>2</sub> solution (Sigma-Aldrich) with DMEM  
20  
21 (11965-118, Life Technologies). 18.13 μM, 36.26 μM, 54.39 μM, and 72.52 μM H<sub>2</sub>O<sub>2</sub>-rich DMEM  
22  
23 were prepared according to the H<sub>2</sub>O<sub>2</sub> concentration in the 0.5 min, 1 min, 1.5 min, and 2 min of  
24  
25 CAP-stimulated DMEM. 100 μL of H<sub>2</sub>O<sub>2</sub>-rich DMEM was transferred to affect the growth of  
26  
27 U87MG cells in each well immediately. The control group was the case that U87MG cells cultured  
28  
29 in DMEM without the CAP treatment. The sample number in each case was 6. Thus, only 600 μL  
30  
31 in 1 mL of plasma-stimulated DMEM were transferred to affect U87MG cells. U87MG cells were  
32  
33 cultured for 2 days before the measurement of cell viability using MTT assay. The sextuplicate  
34  
35 experiments were independently repeated for twice.  
36  
37  
38  
39  
40  
41  
42

43 **Making the CAP-stimulated AgNO<sub>3</sub>-rich DMEM and affecting the growth of glioblastoma**  
44  
45 **cells.** The AgNO<sub>3</sub>-rich DMEM was prepared by mixing 0.01 M silver nitrate solution (Sigma-  
46  
47 Aldrich) with DMEM. During the CAP treatment, 1 mL of medium (DMEM or AgNO<sub>3</sub>-rich  
48  
49 DMEM) in a well of 12-well plate was treated by CAP for 1 min. The gap between the bottom of  
50  
51 12-well plate and the bottom edge of quartz tube was 3 cm. After that, 100 μL of plasma-stimulated  
52  
53 medium (DMEM or AgNO<sub>3</sub>-rich DMEM) was transferred to affect the growth of U87MG cells in  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 each well immediately. The control group was the case that U87MG cells cultured in the medium  
4 (DMEM or AgNO<sub>3</sub>-rich DMEM) without the CAP treatment. The sample number of each case  
5 was 6. U87MG cells were cultured for 3 days before the cell viability was measured. The  
6 sextuplicate experiments were independently repeated for three times.  
7  
8  
9  
10  
11

12  
13  
14 **Cell viability measurement, data and statistics processing.** According to the protocols provided  
15 by manufacturer, the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)  
16 assay was performed. The original experimental data about the cell viability was the absorbance  
17 at 570 nm measured by a H1 microplate reader (Hybrid Technology). To facilitate analyzing data,  
18 the original measured cell viability was processed to be the relative cell viability through the  
19 division between the measured cell viability (absorbance) of U87MG cells cultured in plasma-  
20 stimulated DMEM or H<sub>2</sub>O<sub>2</sub>-rich DMEM to the measured cell viability of U87MG cells cultured  
21 in the untreated DMEM. The measured cell viability of each experiment was equal to the mean  
22 value of 6 samples from 6 wells. The final data shown in this manuscript were the mean  $\pm$  s.d. of  
23 two independently repeated experiments.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 **Intracellular ROS measurement.** The intracellular ROS in the U87MG cells were measured by  
42 using DCFDA-Cellular Reactive Oxygen Species Detection Assay Kit (113851, Abcam). U87MG  
43 cells were seeded in 35 mm easy grip culture dish with a confluence of  $4 \times 10^4$  cells/mL. In each  
44 dish, 2 mL of medium (90% v/v DMEM and 10% v/v FBS) were used to culture U87MG cells for  
45 5 hours in the incubator under the standard culture conditions. 12 mL of 25  $\mu$ M DCFDA solution  
46 was prepared by mixing 18  $\mu$ L of 20 mM DCFDA solution with 12 mL of 1X buffer. After 4 hours  
47 of incubation, the medium in 35 mm dish were removed. 1 mL of 1X buffer was used to wash the  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 cells in dish. 2 mL of 25  $\mu$ M DCFDA solution were used to culture U87MG cells for 40 min in the  
4  
5 incubator under the standard culture conditions. 1 mL of 1X buffer was used to wash the cells in  
6  
7 dish. The cells from control group and experiments groups were finally cultured for 2 hours in the  
8  
9 DMEM without CAP treatment and the CAP-stimulated DMEM, respectively. The CAP-  
10  
11 stimulated DMEM was made by treating 1 mL of DMEM in a well of 12-well plate for 4 min.  
12  
13 Finally, the fluorescent signal of cells in 35 mm dish was detected by a laser scanning confocal  
14  
15 microscope with an excitation wavelength at 488 nm (Zeiss, LSM 710).  
16  
17  
18  
19  
20  
21

## 22 **Results and discussion.**

23  
24 The expression of AQPs in tumor tissues has been widely investigated in past decades [50, 51].  
25  
26 The expression of AQP1 [52-54], AQP8 [55], and AQP9 [56-58] in glioblastoma tissues have been  
27  
28 confirmed. However, the expression of AQPs in glioblastoma cell lines (U87MG) have not been  
29  
30 investigated yet. We first investigated the expression style of AQPs family in U87MG cells. Our  
31  
32 PCR analysis of AQPs family (AQP1-AQP12) showed that only AQP1, AQP3, AQP5, AQP7,  
33  
34 AQP8, AQP9, and AQP11 are expressed in U87MG cells (Fig. 1a). Among these AQPs, the  
35  
36 expression of AQP9 is the most abundant. AQP9 is reported to play important roles in the  
37  
38 malignant progression of brain astrocytic tumors [56], such as counteracting the glioma-associated  
39  
40 lactic acidosis by clearance of glycerol and lactate from the extracellular space [57]. AQP9 has  
41  
42 been proposed to be a new biomarker in glioblastoma diagnosis and a new target for glioblastoma  
43  
44 therapy [56]. So far, only AQP1, AQP3, AQP8, and AQP9 have been reported as the H<sub>2</sub>O<sub>2</sub>  
45  
46 transmembrane channels [41-45]. In addition, AQP8 has been regarded as the most efficient H<sub>2</sub>O<sub>2</sub>  
47  
48 channels among these four AQPs [2, 43]. Thus, AQP8 and AQP9 were chosen to study AQPs'  
49  
50 role in anti-glioblastoma effect of PSM by using siRNA technology. Compared with the control  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 group (sicontrol), the expression of AQP8 (Fig. 1b) and AQP9 (Fig. 1c) in U87MG cells decreased  
4  
5 about 80% and 90% 48 hours after the transfection, respectively. The silencing of AQP8 and AQP9  
6  
7 by siRNA is highly time-sensitive. The expression of AQP8 and AQP9 were lowest 48 hours after  
8  
9 the transfection. Their expression began to recover 72 hours after the transfection.  
10  
11  
12  
13

14  
15 To investigate the role of AQP8 and AQP9 in the anti-glioblastoma capacity of PSM, U87MG  
16  
17 cells with a repressed expression of AQP8 and AQP9 were cultured in the CAP-stimulated DMEM  
18  
19 or H<sub>2</sub>O<sub>2</sub>-rich DMEM without the CAP treatment. The detailed description for the protocols is  
20  
21 illustrated in Methods. For both two treatments, the anti-glioblastoma capacity of PSM increases  
22  
23 when the treatment time in PSM increases (Fig. 2a) or the concentration of H<sub>2</sub>O<sub>2</sub> in H<sub>2</sub>O<sub>2</sub>-rich  
24  
25 DMEM increase (Fig. 2b). This trend is consistent with our previous reports about the application  
26  
27 of PSM on glioblastoma cells treatment [18, 19, 24]. The anti-glioblastoma effect of PSM will not  
28  
29 be obvious until the treatment time of CAP is adequately long (Fig. 2a) or the concentration of  
30  
31 H<sub>2</sub>O<sub>2</sub> is adequately high (Fig. 2b). Knockdown of AQP8 but not AQP9 in U87MG cells can  
32  
33 significantly reduce the anti-glioblastoma capacity of PSM (Fig. 2a) and the toxicity of H<sub>2</sub>O<sub>2</sub>-rich  
34  
35 DMEM (Fig. 2b). This trend is consistent with the previous conclusion that AQP8 is an efficient  
36  
37 H<sub>2</sub>O<sub>2</sub> transmembrane channel [2, 43]. The comparative study about the H<sub>2</sub>O<sub>2</sub> transmembrane  
38  
39 diffusion efficiency of AQP8 and AQP9 is still lacking in biology. Despite AQP9 is most  
40  
41 expressed in U87MG cells, its transmembrane diffusion efficiency for H<sub>2</sub>O<sub>2</sub> may be much less  
42  
43 than AQP8. The estimated diameter of the ar/R constriction region of AQP8 is much larger than  
44  
45 AQP0, 1, 2, 4, and 5 [2]. AQP8 may be the most efficient H<sub>2</sub>O<sub>2</sub> channels among AQP1, 3, and 9.  
46  
47 In addition, so far, dozens of references about the roles of AQP1, 3, and 8 as the H<sub>2</sub>O<sub>2</sub> channels  
48  
49 have been reported [59]. However, only one report has demonstrated that AQP9 is a H<sub>2</sub>O<sub>2</sub> channels  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 recently. In biology, it may be still disputable to conclude that AQP9 is a H<sub>2</sub>O<sub>2</sub> channel. Probably,  
4  
5 due to above reasons, just inhibiting AQP9 but not AQP8 does not result in a noticeable change  
6  
7  
8 on the anti-glioblastoma effect of PSM on U87MG cells. AQP8 still worked when we just silenced  
9  
10 AQP9. Clearly, a more comprehensive study on the role of each member of AQP in the anti-cancer  
11  
12 capacity of PSM should be performed in the further investigation. Nonetheless, silencing specific  
13  
14 AQP in U87MG cells indeed weakens the anti-cancer effect of PSM.  
15  
16  
17  
18  
19

20 The weakened anti-glioblastoma capacity of PSM by inhibiting the expression of AQP8 can be  
21  
22 due to the weakened transmembrane diffusion of H<sub>2</sub>O<sub>2</sub> in U87MG cells. Then, the rise of  
23  
24 intracellular ROS in U87MG cells should also be decreased when the expression of AQP8 is  
25  
26 inhibited. To confirm this, intracellular ROS fluorescent detection measurement was performed.  
27  
28 We observed that the noticeable rise of intracellular ROS in the PSM-treated U87MG cells  
29  
30 disappeared when the expression of AQP8 was inhibited in U87MG cells (Fig. 2c). Thus, AQP8  
31  
32 plays a key intermediate role in the transmembrane diffusion of plasma-originated H<sub>2</sub>O<sub>2</sub> in  
33  
34 U87MG cells. The expression level of specific AQPs in cancer cells may be an important factor in  
35  
36 determining the anti-cancer capacity of PSM.  
37  
38  
39  
40  
41  
42

43 To inhibit the function of AQPs, pharmacological agents such as bumetanide and furosemide [60],  
44  
45 as well as metal atoms such as gold (Au), mercury (Hg), and silver (Ag) [61] have been widely  
46  
47 used as the AQPs-blockers. The blocking mechanism of mercury atom in the channel of AQPs  
48  
49 have been investigated through analyzing the crystal structure of AQPs tetramers with a mercury  
50  
51 atom in each monomer [62]. Silver and other atoms such as gold may block the channel of AQPs  
52  
53 using similar mechanism, though the corresponding structural biology data are still lacking. We  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 have used silver rather than mercury was based on two reasons. First, mercury and corresponding  
4 chemicals with mercury such as mercury chloride evaporate during the standard cell culture  
5 conditions, which rises a potential safety risk to researchers. Second, silver atoms show a better  
6 AQP-blocking property than mercury atoms [61]. For the erythrocytes, 10  $\mu\text{M}$   $\text{Ag}^+$  already causes  
7 about 80% inhibition on water transportation capacity [61]. Inhibiting the transmembrane diffusion  
8 of  $\text{H}_2\text{O}_2$  in leukemia (B1647) cells by 5  $\mu\text{M}$   $\text{AgNO}_3$  have been demonstrated recently [63].  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 In this study, the anti-glioblastoma capacity of the CAP-stimulated  $\text{AgNO}_3$ -rich DMEM and  
21 DMEM was compared. As shown in Fig. 3a, the noticeable anti-glioblastoma effect of the PSM  
22 gradually decreases as the concentration of  $\text{AgNO}_3$  in DMEM increases from 2  $\mu\text{M}$  to 10  $\mu\text{M}$ .  
23 Compared with the effect of silencing AQP8 on the anti-glioblastoma capacity of PSM,  $\text{AgNO}_3$   
24 shows a stronger interference on the anti-glioblastoma capacity of PSM. This phenomenon may  
25 be due to two main faults of  $\text{AgNO}_3$  compared with siRNA technology. First, silver does not target  
26 a specific AQP but may block different AQPs. It is possible that both AQP1, 3, 8, or 9 have been  
27 blocked by silver atoms. On the contrary, we have not inhibited the expression of AQP1 or AQP3  
28 in this study. It is possible that AQP1 and AQP3 also partially contribute to the transmembrane  
29 diffusion of  $\text{H}_2\text{O}_2$ . Second,  $\text{AgNO}_3$  may affect other cellular pathways to U87MG cells other than  
30 just blocking AQPs. For example, silver may react with  $\text{H}_2\text{O}_2$  and form hydroxyl radical, which is  
31 highly reactive with many key molecules including proteins and DNA [64].  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 Obviously,  $\text{AgNO}_3$ -rich DMEM with a high concentration ( $>10 \mu\text{M}$ ) was very toxic to U87MG  
51 cells (Fig. 3a). Because  $\text{NO}_3^-$  with such a low concentration is not toxic to cancer cells [25], the  
52 toxicity of  $\text{AgNO}_3$ -rich DMEM should be mainly due to silver. Silver may react with chloride in  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 DMEM to form silver chloride sediment. However, the noticeable toxicity of  $\text{AgNO}_3$  on U87MG  
4  
5 cells demonstrate that significant silver still dissolves in DMEM. The concentration of  $\text{H}_2\text{O}_2$  in the  
6  
7 CAP-stimulated  $\text{AgNO}_3$ -rich DMEM has also been measured by using Fluorimetric Hydrogen  
8  
9 Peroxide Assay Kit. The increased  $\text{AgNO}_3$  concentration in DMEM does not decrease the  
10  
11 generation of  $\text{H}_2\text{O}_2$  in the CAP-stimulated DMEM (Fig. 3b). Because  $\text{H}_2\text{O}_2$  is the main anti-cancer  
12  
13 reactive species in PSM, the weakened anti-cancer effect of PSM is not due to the consumptive  
14  
15 reaction between  $\text{H}_2\text{O}_2$  and silver.  
16  
17  
18  
19  
20  
21

22 Different tumor tissues express AQPs with quite different levels [50, 51]. Thus, this study provides  
23  
24 a clue to understand the different response of cancer cells to the CAP treatment *in vitro*. For  
25  
26 example, it is found that cancer cells with higher proliferation rate are more sensitive to the CAP  
27  
28 treatment than the cancer cells with lower proliferation rate [65]. Actually, it is also found that the  
29  
30 cancer cells from the high tumorigenic stage tend to express more AQPs than cancer cells from  
31  
32 the low tumorigenic stage [55]. The high AQPs expression in cancer cells from the high  
33  
34 tumorigenic stage may explain the strong sensitivity of these cancer cells to the CAP treatment.  
35  
36  
37  
38  
39  
40

#### 41 **Conclusions.**

42  
43 Aquaporins, the only confirmed transmembrane channels of  $\text{H}_2\text{O}_2$ , play a key intermediate role in  
44  
45 the anti-glioblastoma effect of PSM. Inhibiting the expression of AQP8 in U87MG cells or using  
46  
47 aquaporins-blocker silver atoms significantly weaken the anti-glioblastoma capacity of PSM.  
48  
49 Expression level of aquaporins family in cancer cells significantly affect the anti-cancer effect of  
50  
51 PSM. Because aquaporins are widely but diversely expressed in cancer cells, this study provides  
52  
53 a novel framework to understand the different responses of cancer cells to the CAP treatment.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 **Acknowledgements.** This work was supported in part by GW Institute of Nanotechnology and  
7  
8 National Science Foundation, grant 1465061.  
9

10  
11  
12  
13 **References.**  
14

- 15 [1] Lu X, Naidis GV, Laroussi M, Reuter S, Graves DB, Ostrikov K. Reactive species in non-  
16 equilibrium atmospheric-pressure plasmas: Generation, transport, and biological effects. *Physics*  
17 *Reports*. 2016;630:1-84.  
18 [2] Yan D, Talbot A, Nourmohammadi N, Sherman JH, Cheng X, Keidar M. Toward understanding  
19 the selective anticancer capacity of cold atmospheric plasma—A model based on aquaporins  
20 (Review). *Biointerphases*. 2015;10:040801.  
21 [3] Georgescu N, Lupu AR. Tumoral and normal cells treatment with high-voltage pulsed cold  
22 atmospheric plasma jets. *Plasma Science, IEEE Transactions on*. 2010;38:1949-55.  
23 [4] Kim GJ, Kim W, Kim KT, Lee JK. DNA damage and mitochondria dysfunction in cell apoptosis  
24 induced by nonthermal air plasma. *Applied Physics Letters*. 2010;96:021502.  
25 [5] Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, et al. Cold plasma  
26 selectivity and the possibility of a paradigm shift in cancer therapy. *British journal of cancer*.  
27 2011;105:1295-301.  
28 [6] Keidar M. Plasma for cancer treatment. *Plasma Sources Science and Technology*.  
29 2015;24:033001.  
30 [7] Fridman G, Shereshevsky A, Jost MM, Brooks AD, Fridman A, Gutsol A, et al. Floating Electrode  
31 Dielectric Barrier Discharge Plasma in Air Promoting Apoptotic Behavior in Melanoma Skin Cancer  
32 Cell Lines. *Plasma Chemistry and Plasma Processing*. 2007;27:163-76.  
33 [8] Yan X, Xiong Z, Zou F, Zhao S, Lu X, Yang G, et al. Plasma-Induced Death of HepG2 Cancer Cells:  
34 Intracellular Effects of Reactive Species. *Plasma Processes and Polymers*. 2012;9:59-66.  
35 [9] Zhao S, Xiong Z, Mao X, Meng D, Lei Q, Li Y, et al. Atmospheric pressure room temperature  
36 plasma jets facilitate oxidative and nitrative stress and lead to endoplasmic reticulum stress  
37 dependent apoptosis in HepG2 cells. *PloS one*. 2013;8:e73665.  
38 [10] Keidar M, Shashurin A, Volotskova O, Ann Stepp M, Srinivasan P, Sandler A, et al. Cold  
39 atmospheric plasma in cancer therapy. *Physics of Plasmas*. 2013;20:057101.  
40 [11] Zhu W, Lee SJ, Castro NJ, Yan D, Keidar M, Zhang LG. Synergistic Effect of Cold Atmospheric  
41 Plasma and Drug Loaded Core-shell Nanoparticles on Inhibiting Breast Cancer Cell Growth.  
42 *Scientific reports*. 2016;6:21974.  
43 [12] Yan D, Sherman JH, Keidar M. Cold atmospheric plasma, a novel promising anti-cancer  
44 treatment modality. *Oncotarget*. 2016; Epub ahead of print.  
45 [13] Vandamme M, Robert E, Dozias S, Sobilo J, Lerondel S, Le Pape A, et al. Response of human  
46 glioma U87 xenografted on mice to non thermal plasma treatment. *Plasma medicine*. 2011;1:27-  
47 43.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [14] Brulle L, Vandamme M, Ries D, Martel E, Robert E, Lerondel S, et al. Effects of a non thermal  
4 plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic  
5 pancreatic carcinoma model. *PloS one*. 2012;7:e52653.  
6  
7 [15] Walk RM, Snyder JA, Srinivasan P, Kirsch J, Diaz SO, Blanco FC, et al. Cold atmospheric plasma  
8 for the ablative treatment of neuroblastoma. *Journal of pediatric surgery*. 2013;48:67-73.  
9  
10 [16] Tanaka H, Mizuno M, Ishikawa K, Nakamura K, Kajiyama H, Kano H, et al. Plasma-Activated  
11 Medium Selectively Kills Glioblastoma Brain Tumor Cells by Down-Regulating a Survival Signaling  
12 Molecule, AKT Kinase. *Plasma Medicine*. 2011;1:265-277.  
13  
14 [17] Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Mizuno M, Ishikawa K, et al. Effect of indirect  
15 nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic  
16 chemo-resistant ovarian cancer cells in vitro and in vivo. *PloS one*. 2013;8:e81576.  
17  
18 [18] Yan D, Sherman JH, Cheng X, Ratovitski E, Canady J, Keidar M. Controlling plasma stimulated  
19 media in cancer treatment application. *Applied Physics Letters*. 2014;105:224101.  
20  
21 [19] Yan D, Talbot A, Nourmohammadi N, Cheng X, Canady J, Sherman J, et al. Principles of using  
22 Cold Atmospheric Plasma Stimulated Media for Cancer Treatment. *Scientific reports*.  
23 2015;5:18339.  
24  
25 [20] Mohades S, Laroussi M, Sears J, Barekzi N, Razavi H. Evaluation of the effects of a plasma  
26 activated medium on cancer cells. *Physics of Plasmas*. 2015;22:122001.  
27  
28 [21] Kumar N, Park JH, Jeon SN, Park BS, Choi EH, Attri P. The action of microsecond-pulsed  
29 plasma-activated media on the inactivation of human lung cancer cells. *Journal of Physics D:  
30 Applied Physics*. 2016;49:115401.  
31  
32 [22] Kurake N, Tanaka H, Ishikawa K, Kondo T, Sekine M, Nakamura K, et al. Cell survival of  
33 glioblastoma grown in medium containing hydrogen peroxide and/or nitrite, or in plasma-  
34 activated medium. *Arch Biochem Biophys*. 2016;605:102-108.  
35  
36 [23] Adachi T, Nonomura S, Horiba M, Hirayama T, Kamiya T, Nagasawa H, et al. Iron stimulates  
37 plasma-activated medium-induced A549 cell injury. *Scientific reports*. 2016;6:20928.  
38  
39 [24] Yan D, Nourmohammadi N, Talbot A, Sherman JH, Keidar M. The strong anti-glioblastoma  
40 capacity of the plasma-stimulated lysine-rich medium. *Journal of Physics D: Applied Physics*.  
41 2016;49:274001.  
42  
43 [25] Girard PM, Arbabian A, Fleury M, Bauville G, Puech V, Dutreix M, et al. Synergistic Effect of  
44 H2O2 and NO2 in Cell Death Induced by Cold Atmospheric He Plasma. *Scientific reports*.  
45 2016;6:29098.  
46  
47 [26] Yan D, Nourmohammadi N, Bian K, Murad F, Sherman JH, Keidar M. Stabilizing the cold  
48 plasma-stimulated medium by regulating medium's composition. *Scientific reports*.  
49 2016;6:26016.  
50  
51 [27] Adachi T, Tanaka H, Nonomura S, Hara H, Kondo S, Hori M. Plasma-activated medium induces  
52 A549 cell injury via a spiral apoptotic cascade involving the mitochondrial-nuclear network. *Free  
53 radical biology & medicine*. 2014;79C:28-44.  
54  
55 [28] Judee F, Fongia C, Ducommun B, Yousfi M, Lobjois V, Merbahi N. Short and long time effects  
56 of low temperature Plasma Activated Media on 3D multicellular tumor spheroids. *Scientific  
57 reports*. 2016;6:21421.  
58  
59 [29] Kim SJ, Chung TH, Bae SH, Leem SH. Induction of apoptosis in human breast cancer cells by  
60 a pulsed atmospheric pressure plasma jet. *Applied Physics Letters*. 2010;97:023702.


- 1  
2  
3 [30] Shashurin A, Stepp MA, Hawley TS, Pal-Ghosh S, Brieda L, Bronnikov S, et al. Influence of  
4 Cold Plasma Atmospheric Jet on Surface Integrin Expression of Living Cells. *Plasma Processes and*  
5 *Polymers*. 2010;7:294-300.
- 7 [31] Kim JY, Ballato J, Foy P, Hawkins T, Wei Y, Li J, et al. Apoptosis of lung carcinoma cells induced  
8 by a flexible optical fiber-based cold microplasma. *Biosensors & bioelectronics*. 2011;28:333-8.
- 10 [32] Berekzi N, Laroussi M. Dose-dependent killing of leukemia cells by low-temperature plasma.  
11 *Journal of Physics D: Applied Physics*. 2012;45:422002.
- 13 [33] Kaushik N, Kaushik NK, Kim CH, Choi EH. Oxidative Stress and Cell Death Induced in U-937  
14 Human Monocytic Cancer Cell Line by Non-Thermal Atmospheric Air Plasma Soft Jet. *Science of*  
15 *Advanced Materials*. 2014;6:1740-51.
- 17 [34] Kaushik NK, Kaushik N, Park D, Choi EH. Altered Antioxidant System Stimulates Dielectric  
18 Barrier Discharge Plasma-Induced Cell Death for Solid Tumor Cell Treatment. *PloS one*.  
19 2014;9:e103349.
- 21 [35] Gibson AR, McCarthy HO, Ali AA, O'Connell D, Graham WG. Interactions of a Non-Thermal  
22 Atmospheric Pressure Plasma Effluent with PC-3 Prostate Cancer Cells. *Plasma Processes and*  
23 *Polymers*. 2014;11:1142-1149.
- 25 [36] Kang SU, Cho JH, Chang JW, Shin YS, Kim KI, Park JK, et al. Nonthermal plasma induces head  
26 and neck cancer cell death: the potential involvement of mitogen-activated protein kinase-  
27 dependent mitochondrial reactive oxygen species. *Cell death & disease*. 2014;5:e1056.
- 29 [37] Tanaka H, Mizuno M, Toyokuni S, Maruyama S, Kodera Y, Terasaki H, et al. Cancer therapy  
30 using non-thermal atmospheric pressure plasma with ultra-high electron density. *Physics of*  
31 *Plasmas*. 2015;22:122004.
- 33 [38] Yokoyama M, Johkura K, Sato T. Gene expression responses of HeLa cells to chemical species  
34 generated by an atmospheric plasma flow. *Biochem Biophys Res Commun*. 2014;450:1266-71.
- 36 [39] Borgnia M, Nielsen S, Engel A, Agre P. Cellular and molecular biology of the aquaporin water  
37 channels. *Annual review of biochemistry*. 1999;68:425-58.
- 39 [40] Wu B, Beitz E. Aquaporins with selectivity for unconventional permeants. *Cellular and*  
40 *molecular life sciences*. 2007;64:2413-21.
- 42 [41] Bienert GP, Chaumont F. Aquaporin-facilitated transmembrane diffusion of hydrogen  
43 peroxide. *Biochimica et Biophysica Acta (BBA)-General Subjects*. 2014;1840:1596-604.
- 45 [42] Miller EW, Dickinson BC, Chang CJ. Aquaporin-3 mediates hydrogen peroxide uptake to  
46 regulate downstream intracellular signaling. *Proceedings of the National Academy of Sciences*.  
47 2010;107:15681-6.
- 49 [43] Almasalmeh A, Krenc D, Wu B, Beitz E. Structural determinants of the hydrogen peroxide  
50 permeability of aquaporins. *The FEBS journal*. 2014;281:647-56.
- 52 [44] Watanabe S, Moniaga CS, Nielsen S, Hara-Chikuma M. Aquaporin-9 facilitates membrane  
53 transport of hydrogen peroxide in mammalian cells. *Biochemical and biophysical research*  
54 *communications*. 2016;471:191-7.
- 56 [45] Herrera M, Hong NJ, Garvin JL. Aquaporin-1 transports NO across cell membranes.  
57 *Hypertension*. 2006;48:157-64.
- 59 [46] Yang B, Kim JK, Verkman A. Comparative efficacy of HgCl<sub>2</sub> with candidate aquaporin-1  
60 inhibitors DMSO, gold, TEA<sup>+</sup> and acetazolamide. *FEBS letters*. 2006;580:6679-84.
- [47] Niemietz CM, Tyerman SD. New potent inhibitors of aquaporins: silver and gold compounds  
inhibit aquaporins of plant and human origin. *FEBS letters*. 2002;531:443-7.

- 1  
2  
3 [48] Volotskova O, Hawley TS, Stepp MA, Keidar M. Targeting the cancer cell cycle by cold  
4 atmospheric plasma. *Scientific reports*. 2012;2:636.
- 5 [49] Cheng X, Sherman J, Murphy W, Ratovitski E, Canady J, Keidar M. The Effect of Tuning Cold  
6 Plasma Composition on Glioblastoma Cell Viability. *PloS one*. 2014;9:e98652.
- 7 [50] Verkman A, Hara-Chikuma M, Papadopoulos MC. Aquaporins—new players in cancer biology.  
8 *Journal of molecular medicine*. 2008;86:523-9.
- 9 [51] Papadopoulos MC, Saadoun S. Key roles of aquaporins in tumor biology. *Biochimica et*  
10 *Biophysica Acta (BBA)-Biomembranes*. 2015;1848:2576-83.
- 11 [52] El Hindy N, Bankfalvi A, Herring A, Adamzik M, Lambertz N, Zhu Y, et al. Correlation of  
12 aquaporin-1 water channel protein expression with tumor angiogenesis in human astrocytoma.  
13 *Anticancer research*. 2013;33:609-13.
- 14 [53] Oshio K, Binder DK, Liang Y, Bollen A, Feuerstein B, Berger MS, et al. Expression of the  
15 Aquaporin-1 Water Channel in Human Glial Tumors. *Neurosurgery*. 2005;56:375-81.
- 16 [54] Deb P, Pal S, Dutta V, Boruah D, Chandran VM, Bhatoe HS. Correlation of expression pattern  
17 of aquaporin-1 in primary central nervous system tumors with tumor type, grade, proliferation,  
18 microvessel density, contrast-enhancement and perilesional edema. *Journal of cancer research*  
19 *and therapeutics*. 2012;8:571.
- 20 [55] Zhu SJ, Wang KJ, Gan SW, Xu J, Xu SY, Sun SQ. Expression of aquaporin8 in human  
21 astrocytomas: correlation with pathologic grade. *Biochem Biophys Res Commun*. 2013;440:168-  
22 72.
- 23 [56] Tan G, Sun S, Yuan D. Expression of the water channel protein aquaporin-9 in human  
24 astrocytic tumours: correlation with pathological grade. *Journal of International Medical*  
25 *Research*. 2008;36:777-82.
- 26 [57] Warth A, Mittelbronn M, Hülper P, Erdlenbruch B, Wolburg H. Expression of the water  
27 channel protein aquaporin-9 in malignant brain tumors. *Applied Immunohistochemistry &*  
28 *Molecular Morphology*. 2007;15:193-8.
- 29 [58] Jelen S, Parm Ulhøi B, Larsen A, Frøkiær J, Nielsen S, Rützler M. AQP9 expression in  
30 glioblastoma multiforme tumors is limited to a small population of astrocytic cells and CD15  
31 (+)/CalB (+) leukocytes. *PloS one*. 2013;8:e75764.
- 32 [59] Bienert GP, Chaumont F. Aquaporin-facilitated transmembrane diffusion of hydrogen  
33 peroxide. *Biochimica et biophysica acta*. 2014;1840:1596-604.
- 34 [60] Devuyst O, Yool AJ. Aquaporin-1: new developments and perspectives for peritoneal dialysis.  
35 *Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis*.  
36 2010;30:135-41.
- 37 [61] Yang B, Kim JK, Verkman AS. Comparative efficacy of HgCl<sub>2</sub> with candidate aquaporin-1  
38 inhibitors DMSO, gold, TEA<sup>+</sup> and acetazolamide. *FEBS Lett*. 2006;580:6679-84.
- 39 [62] Savage DF, Stroud RM. Structural basis of aquaporin inhibition by mercury. *Journal of*  
40 *molecular biology*. 2007;368:607-17.
- 41 [63] Vieceli Dalla Sega F, Zambonin L, Fiorentini D, Rizzo B, Caliceti C, Landi L, et al. Specific  
42 aquaporins facilitate Nox-produced hydrogen peroxide transport through plasma membrane in  
43 leukaemia cells. *Biochimica et biophysica acta*. 2014;1843:806-14.
- 44 [64] He D, Miller CJ, Waite TD. Fenton-like zero-valent silver nanoparticle-mediated hydroxyl  
45 radical production. *Journal of Catalysis*. 2014;317:198-205.
- 46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

[65] Naciri M, Dowling D, Al-Rubeai M. Differential Sensitivity of Mammalian Cell Lines to Non-Thermal Atmospheric Plasma. *Plasma Processes and Polymers*. 2014;11:391-400.


## Figures



**Figure 1. The expression of AQPs in U87MG cells and the inhibited expression of AQP8 and AQP9 by siRNA.** (a) RT-PCR analysis of AQP1-AQP12 expression in U87MG cells. cDNA of U87MG cells was used as PCR template and the PCR products were resolved in agarose gel (see Table 1 for predicted PCR products size). (b) Quantitative RT-PCR analysis of expression of AQP8 and AQP9 after siRNA knockdown. RNA was prepared from U87MG cells after knockdown of AQP8 or AQP9 for 48 hr. A universal negative siRNA was used as a control (sicontrol). And then cDNA was synthesized and used as template for PCR. The expression of AQP8 and AQP9 was normalized to the expression of Actin. The results were an average of three different repeats. Student's t-test was performed and the significance is indicated as \*\*\*  $p < 0.005$ , \*\*  $p < 0.01$ , and \*  $p < 0.05$ .



**Figure 2. Silencing the expression of AQP8 significantly weakens the anti-glioblastoma capacity of PSM.** The anti-glioblastoma capacity of PSM (a) and H<sub>2</sub>O<sub>2</sub>-rich DMEM (b) on U87MG cells (si-control, siAQP8, and siAQP9). Results are presented as the mean  $\pm$  s.d. of two independently repeated experiments performed in sextuplicate. Student's t-test was performed and the significance is indicated as \*\*\*  $p < 0.005$ , \*\*  $p < 0.01$ , and \*  $p < 0.05$ . (c) The rise of intracellular reactive oxygen species (ROS) in U87MG cells (si-control and si-AQP8) was measured by DCFDA-Cellular Reactive Oxygen Species Detection Assay Kit using laser scanning confocal microscope. Scale bar = 100  $\mu$ m.



**Figure 3. AgNO<sub>3</sub> weakens the anti-glioblastoma capacity of PSM.** (a) The anti-glioblastoma capacity of the CAP-stimulated AgNO<sub>3</sub>-rich DMEM (2 - 14 µM) and DMEM (0 µM). The control group represents the case that U87MG cells cultured in the untreated DMEM or in the untreated AgNO<sub>3</sub>-rich DMEM. Results are presented as the mean ± s.d. of experiments performed in sextuplicate. Student's t-test was performed and the significance is indicated as \*\*\* p < 0.005, \*\* p < 0.01, and \* p < 0.05. (b) The generation of H<sub>2</sub>O<sub>2</sub> in the CAP-stimulated AgNO<sub>3</sub>-rich DMEM (2 - 16 µM) and DMEM (0 µM). Results are presented as the mean ± s.d. of three repeated experiments.